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A number of studies have shown pharmacologic evidence indicating that stimulation of
type I dopamine receptor (DR), favors T-helper-17 (Th17)-mediated immunity involved
in experimental autoimmune encephalomyelitis (EAE) and in some other inflammatory
disorders. Nevertheless, the lack of drugs that might discriminate between DRD1 and
DRD5 has made the pharmacological distinction between the two receptors difficult. We
have previously shown genetic evidence demonstrating a relevant role of DRD5-signaling
in dendritic cells (DCs) favoring the CD4+ T-cell-driven inflammation in EAE. However,
the role of DRD5-signaling confined to CD4+ T-cells in the development of EAE is
still unknown. Here, we analyzed the functional role of DRD5-signaling in CD4+ T-cell-
mediated responses and its relevance in EAE by using a genetic approach. Our results
show that DRD5-signaling confined to naive CD4+ T-cells exerts a pro-inflammatory
effect promoting the development of EAE with a stronger disease severity. This
pro-inflammatory effect observed for DRD5-signaling in naive CD4+ T-cells was related
with an exacerbated proliferation in response to T-cell activation and to an increased
ability to differentiate toward the Th17 inflammatory phenotype. On the other hand, quite
unexpected, our results show that DRD5-signaling confined to Tregs strengthens their
suppressive activity, thereby dampening the development of EAE manifestation. This
anti-inflammatory effect of DRD5-signaling in Tregs was associated with a selective
increase in the expression of glucocorticoid-induced tumor necrosis factor receptor-
related protein (GITR), which has been described to play a critical role in the expansion
Abbreviations: Ab, antibody; CFSE, carboxyfluorescein succinimidyl ester; CNS, central nervous system; CDn, cluster of
differentiation n; CFA, complete Freund’s adjuvant; CTLA4, cytotoxic T-lymphocyte antigen 4; DCs, dendritic cells; DR,
Dopamine Receptor; DRDn, DR Dn; DRDnKO, DRDn Knockout; EAE, Experimental Autoimmune Encephalomyelitis;
IFN-n, interferon n; IL-n, interleukin n; mAb, monoclonal antibody; MFI, mean fluorescence intensity; MOG, myelin
oligodendrocyte glicoprotein; OVA, ovalbumin; pOT-II, peptide OVA323–339; pMOG, peptideMOG35–55; PE, phycoerythrin;
PMA, phorbol 12-myristate 13-acetate; RORγt, RAR-related orphan receptor gamma; STAT3, signal transducer and
activator of transcription 3; TGF-β, transforming growth factor β; Tregs, regulatory T-cells; Tbet, T-box transcrption
factor encoded by TBX21; Thn, T helper n; WT, wild-type.
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of Tregs. Our findings here indicate a complex role for DRD5-signaling in CD4+ T-cells-
driven responses potentiating early inflammation mediated by effector T-cells in EAE, but
exacerbating suppressive activity in Tregs and thereby dampening disease manifestation
in late EAE stages.
Keywords: Th17 response, T-cell activation, regulatory T-cells, dopamine, knockout mice, experimental
autoimmune encephalomyelitis, neuroimmunology
INTRODUCTION
During last 15 years dopamine has emerged as a major regulator
of inflammation. All five dopamine receptors (DRs, DRD1-
DRD5) have been found to be expressed in immune cells,
including dendritic cells (DCs) and T-cells among others,
where they exert a complex regulation of immunity (Pacheco
et al., 2014). The outcome of the dopamine effects in the
immune response depends inmany factors, including differential
expression of DRs in the immune cells present in the inflamed
tissue, the local levels of dopamine and the signaling coupled
to and the affinity of the different DRs involved. Current
evidence has indicated that stimulation of low-affinity DRs, for
instance DRD1 and DRD2, are coupled to anti-inflammatory
mechanisms, thereby dampening inflammation (Shao et al.,
2013; Yan et al., 2015). Conversely, signaling triggered by
high-affinity DRs, including DRD3 and DRD5, has been found
consistently to promote inflammation (Prado et al., 2012, 2018;
Contreras et al., 2016).
Multiple sclerosis (MS) is an inflammatory disorder involving
a CD4+ T-cells driven response against the myelin sheath in
the central nervous system (CNS). Previous evidence suggested
that T-helper-1 (Th1) as well as T-helper-17 (Th17) cells are
the phenotypes of autoreactive T-cells involved in MS and its
mouse model, the experimental autoimmune encephalomyelitis
(EAE; Dardalhon et al., 2008; Oukka, 2008). Importantly,
DCs by producing interleukin 12 (IL-12) and IL-23, might
induce the differentiation of naive CD4+ T-cells into Th1 and
Th17 cells respectively (Haines et al., 2013; O’Connor et al.,
2013). Consistent with the prominent role of dopamine in
regulating adaptive immunity, relevant effects for dopaminergic-
signaling have been found in MS (Prado et al., 2012, 2018).
In this regard, CD4+ T-cells infiltrate the CNS where they
can be exposed to dopamine and other neurotransmitters.
In fact, striatal dopamine levels are significantly altered in
mouse models of MS (Balkowiec-Iskra et al., 2007). Accordingly,
emerging evidence has shown a relevant role of type I DRs
(including DRD1 and DRD5) in the regulation of CD4+ T-cell-
mediated autoimmune response involved in human individuals
undergoing MS and in EAE (Prado et al., 2013). In this regard,
type I DRs have been described to be expressed in DCs (Nakano
et al., 2008; Prado et al., 2012) and CD4+ T-cells from human
and mouse origin (Kipnis et al., 2004; Cosentino et al., 2007; Kim
et al., 2013; Franz et al., 2015).
The first work addressing the role of DRs in T-cell mediated
immunity, showed that antagonizing type I DRs expressed
on human DCs altered acquisition of functional phenotype
by naive CD4+ T-cells increasing the Th1-to-Th17 ratio in
co-cultures of DCs and T-cells in vitro (Nakano et al., 2008).
Moreover, the same authors reported later that human DCs
contain intracellular vesicles loaded with dopamine, which are
released during Ag-presentation to naive CD4+ T-cells in vitro
(Nakano et al., 2009). The in vivo relevance of these observations
was evaluated by using a pharmacological approach in EAE
(Nakano et al., 2008). In that study, the treatment of mice with
the systemic administration of a type I DRs antagonist, (R)-
(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-
1H-3-benzazepine hydrochloride (SCH23390), reduced disease
severity by impairing the Th17 response. However, this
pharmacologic approach does not allow the discrimination
between the effects mediated by DRD5 or DRD1 since the
drug inhibits both type I DRs with similar affinities (Bourne,
2001). Furthermore, this study could not identify the cell-type
responsible for the anti-inflammatory effect of type I DRs
antagonism. Importantly, we have contributed to elucidate
this mechanism using a genetic approach that allows us to
determine the contribution of DRD5-signaling in DCs and
its consequences in EAE development. In agreement with
previous studies (Nakano et al., 2008), we demonstrate that
DRD5-deficient mice exhibited delayed EAE progression with
reduced severity compared with normal mice (Prado et al., 2012).
In addition, we demonstrated that DRD5-deficiency confined
to DCs resulted in exacerbated activation of signal transducer
and activator of transcription 3 (STAT3), triggering impaired
production of IL-12 and IL-23 with a consequent attenuation
in Th1 and Th17 responses and reduced EAE manifestation
(Prado et al., 2018). Nevertheless, the extent of attenuation
of disease severity was stronger when EAE manifestation was
compared between wild-type (WT) and general DRD5 knockout
(DRD5KO) mice than when comparing WT animals with mice
harboring DRD5-deficiency confined to DCs, suggesting that
DRD5 expressed in other cell types different of DCs were also
relevant in the regulation of EAE development (Prado et al.,
2012).
Addressing the dopaminergic regulation of CD4+ T-cells
mediated by type I DRs, pharmacological evidence has suggested
that signaling triggered by these receptors in human T-cells
in vitro favors the differentiation toward the Th2 phenotype
(Nakano et al., 2009). Another study performed in a mouse
model of ovalbumin (OVA)-induced acute asthma shows that
pharmacologic antagonism of type I DRs impaired Th17 function
and thereby ameliorated the allergic response (Gong et al.,
2013). In addition, our previous results using a genetic
approach have shown that DRD5-stimulation in mouse CD4+
T-cells favors T-cell activation and without detectable effects
in Th1 differentiation when activated with Abs to CD3 and
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CD28 and a Th1-biased mixture of blocking Abs and cytokine
milieu in vitro (Franz et al., 2015). Regarding the role of
type I DRs on Tregs physiology, two independent groups have
shown pharmacological evidence indicating that, by stimulating
DRD1/DRD5, dopamine reduces the suppressive function of
Tregs (Kipnis et al., 2004; Cosentino et al., 2007). This
dopamine-mediated inhibitory mechanism involves a reduction
in IL-10 and transforming growth factor β (TGF-β) production
and diminished expression of cytotoxic T-lymphocyte antigen
4 (CTLA4), which participate in the cytokine-mediated and
contact-mediated suppression exerted by Tregs, respectively.
Together, these findings support an important role for type I DRs
in the regulation of CD4+ T-cells physiology and reveal a relevant
involvement of these receptors in autoimmunity. Nonetheless,
the precise contribution of DRD1- and DRD5-signaling in the
regulation of the CD4+ T-cell mediated autoimmune response
associated to EAE remains unknown.
In this study, we analyzed the precise role of DRD5-signaling
in the CD4+ T-cell response in vivo using a genetic approach.
For this purpose, we dissected the role of DRD5 expressed in
naive CD4+ T-cells and Tregs from that of DRD5 expressed
in other hematopoietic cells in EAE. Afterward, the role
of DRD5 expressed in CD4+ T-cells in inflammation was
validated in other in vivo paradigms. Our results indicate
that DRD5-signaling in CD4+ T-cells favors T-cell activation
and contributes significantly to the differentiation toward
the Th17-inflammatory phenotype in vivo. Furthermore, our
data show unexpectedly that DRD5-signaling potentiates the
suppressive activity of Tregs in vivo and in vitro. Thus,
our findings indicate that DRD5-signaling in CD4+ T-cells
plays a dual role in EAE development favoring early to the
Th17-mediated inflammation and later contributing to the
suppressive activity of Tregs.
MATERIALS AND METHODS
Animals
C57BL/6 WT (cd45.2+/+) mice and B6.SJL-Ptprca (cd45.1+/+)
mice in the C57BL/6 background were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). DRD5KO mice
were kindly donated by Dr. David Sibley (Hollon et al.,
2002), which were back-crossed for at least ten-generations
in the C57BL/6 (cd45.2+/+) genetic background. OVA-specific
OT-II transgenic mice expressing specific T-cell receptors
(TCRs) for I-Ab/OVA323–339 in the C57BL/6 (cd45.2+/+) genetic
background were gently donated by Dr. María Rosa Bono
(Ureta et al., 2007). DRD5KO/OT-II mice were generated by
crossing parental DRD5KO and OT-II mice. Six-to-10 weeks old
mice were used in all experiments. All mice were maintained
and manipulated according to institutional guidelines at the
pathogen-free facility of the Fundación Ciencia and Vida.
Reagents
Monoclonal antibodies (mAbs) for flow cytometry: anti-FoxP3
(clone FJK-16S) conjugated to Phycoerythrin (PE)-Cyanine
7 (Cy7) and Allophycocyanin (APC), and anti-IFN-γ (clone
XMG1.2) conjugated to PE-Cy7 were obtained from eBioscience
(San Diego, CA, USA). Anti-CD4 (clone GK1.5) conjugated
to APC and APC-Cy7; anti-CD25 (clone PC61) conjugated
to Fluorescein isothiocyanate (FITC); anti-CD44 (clone IM7)
conjugated to PE; anti-CD62L (clone MEL14) conjugated to
APC-Cy7; anti-IL-17A (clone TC11-181710.1) conjugated
to APC; anti-CD45.2 (clone 104) conjugated to PE-Cy7;
anti-CD45.1 (clone A20) conjugated to Brilliant Violet
(Bv)421; anti-CTLA4 (clone UC10-4139) conjugated to
Bv421; anti-ICOS (clone C398.4A) conjugated to PE-Cy7;
anti-CD39 (clone Duha59) conjugated to PE; anti-CD73 (clone
Ty/11.8) conjugated to Peridin-Chlorophyll (PerCP); anti-CCR6
(clone 29-2L17) conjugated to APC; anti-glucocorticoid-
induced tumor necrosis factor receptor-related protein (GITR;
clone YGITR756) conjugated to PE-Cy7; anti-CD104 (clone
2E7) conjugated to Pacific Blue; anti-B220 (clone RA3-6B2)
conjugated to PerCP; anti-TCRVα2 (clone B20.1) conjugated
to PE and TCRVβ5 (clone MR9-4) conjugated to APC were
purchased from Biolegend (San Diego, CA, USA). mAbs for
Cell Culture: the followings mAbs low in endotoxins and azida
free (LEAF) were purchased from Biolegend: anti-IL-4 (clone
11B11), anti-CD28 (clone 37.51), anti-CD3ε (clone 145-2C11),
anti-IFN-γ (clone AN-18) and anti-IL-2 (clone JES6-1A12).
Carrier-Free cytokines TGF-β3, TGF-β1, IL-6, IL-12, IL-23,
IL-1β and IL-2 were purchased from Biolegend. Zombie AquaTM
Fixable Viability dye detectable by flow cytometry was purchased
from Biolegend. Phorbol 12-myristate 13-acetate (PMA) and
ionomycin were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Cell Trace Carboxyfluorescein succinimidyl ester (CFSE),
Brefeldin A and Fetal Bovine Serum (FBS) were obtained from
Life Technologies (Carlsbad, CA, USA). The peptide derived
from myelin oligodendrocyte glycoprotein (pMOG35–55) was
purchased from GeneTel Laboratories (Madison, WI, USA). The
peptide derived from the chicken ovalbumin (OVA323–339; OT-II
peptide or pOT-II) was purchased from Genescript (Piscataway,
NJ, USA). Freund’s Complete Adjuvant (CFA) was purchased
from Thermo Scientific. Bovine Serum Albumin (BSA) was
purchased to Rockland (Limerick, PA, USA).
Generation of Bone Marrow Chimeras
Five-to-six weeks old B6.SJL-Ptprca (cd45.1+/+) mice were
lethally irradiated with two doses of 550 rad each (source of
Co60) separated for 3 h. One-day later, irradiated mice received
the i.v. transference of bone marrow precursors (107 cells per
mouse) obtained fromWT (cd45.2+/+) or DRD5KO (cd45.2+/+)
donor mice and maintained for 8 weeks with antibiotics
(Trimethroprim and Sulfadoxine; Gorban 0.1% purchased from
Merck Animal Health, Madison, NJ, USA) in the drinking water.
The percentage of chimerism was determined as the percentage
of CD45.2+ cells from the CD45+ leukocytes in peripheral blood,
typically fluctuating between 80% and 85% (see Supplementary
Figure S1). Bone marrow precursors were obtained from femurs
and tibias as described before (Inaba et al., 1992).
EAE Induction and Evaluation
Mice were injected s.c. with 50 µg pMOG (Genetel Laboratories,
Madison, WI, USA) emulsified in complete Freund’s adjuvant
(CFA; Invitrogen) supplemented with heat-inactivated
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Mycobacterium tuberculosis H37 RA (Difco Laboratories,
Detroit, MI, USA). In addition, mice received 500 ng pertussis
toxin (Calbiochem, La Jolla, CA, USA) i.p. on days 0 and 2.
Clinical signs were assessed daily according to the following
scoring criteria: 0, no detectable signs; 1, flaccid tail; 2, hind limb
weakness or abnormal gait; 3, complete hind limb paralysis; 4,
paralysis of fore and hind limbs; and 5, moribund or death. In
some EAE experiments, total splenic CD4+ T-cells were purified
by negative selection using magnetic beads-based kit (MACSr,
Miltenyi Biotec, Bergisch Gladbach, Germany) and i.v. injected
(5 × 106 cells per mouse) 24 h before EAE induction. In
other EAE experiments, splenic naive (CD25−CD62L+CD44−)
CD4+ T-cells were purified by cell-sorting and i.v. injected
(3 × 106 cells per mouse) 24 h before EAE induction. In
other experiments splenic Tregs (CD4+ CD25high T-cells) were
purified by cell-sorting and i.v. injected (7× 105 cells per mouse)
24 h before EAE induction.
CD4+ T-Cell Isolation and Activation
in Vitro
Total CD4+ T-cells were obtained by negative selection of
splenocytes (MACSr). Naive (CD4+ CD25−) T-cell isolation
was achieved by cell sorting using a FACS Aria II (BD, Franklin
Lakes, NJ, USA), obtaining purities over 98%. Splenic DCs were
purified using a CD11c+ magnetic selection kit (MACSr). All
in vitro experiments were performed using complete IMDM
medium (Life Technologies) 10% FBS. To assess proliferation,
naive T-cells from OT-II mice were stained with CFSE (10 µM
as indicated in figure legends) and cultured on a 5:1 (T-cells:DCs)
ratio onU-bottom 96-well plates in the presence of OT-II peptide
(OVA323–339, pOT-II; 200 ng/ml) for 2 or 3 days. T-cell activation
was determined as IL-2 secretion in the co-culture supernatant
by ELISA as previously described (González et al., 2013). The
extent of T-cell proliferation was determined as the percentage
of dilution of CFSE-associated fluorescence by flow cytometry.
CD4+ T-Cell Differentiation in Vitro
Naive (CD4+CD62L+CD44−CD25−) T-cell were isolated by
cell-sorting and stimulated with 50 ng/well of plate-bound
anti-CD3 and 2 µg/mL soluble anti-CD28 Abs on flat-bottom
96-well plates (Thermo Scientific) for 5 days. To force the
differentiation of the different Th phenotypes, naïve CD4+
T-cells were incubated in the conditions indicated above, in
addition to a mixture of cytokines and blocking antibodies:
Th1: 20 ng/mL IL-12, 10 ng/mL IL-2 and 5 µg/mL anti-IL-4;
non-pathogenic Th17 (Th17np): during the first 2 days with
25 ng/mL IL-6, 5 ng/mL TGF-β1, 20 ng/mL IL-1β, 5 µg/mL anti-
IL-4, 5 µg/mL anti-IL-2 and 5 µg/mL anti-IFN-γ and during the
last 3 days with 25 ng/mL IL-6, 5 ng/mL TGF-β1; pathogenic
Th17 (Th17p): during the first 2 days with 25 ng/mL IL-6,
5 ng/mL TGF-β3, 20 ng/mL IL-1β, 5 µg/mL anti-IL-4, 5 µg/mL
anti-IL-2 and 5µg/mL anti-IFN-γ and during the last 3 days with
25 ng/mL IL-6, 20 ng/mL IL-1β and 20 ng/mL IL-23. At different
incubation times, cells were assessed for gene expression real time
RT-PCR.
Quantitative RT-PCR
Total RNA extracted from cells using the Total RNA EZNA
kit (Omega Bio-Tek, Norcross, GA, USA), was DNase-
digested using the TURBO DNA-free kit (Ambion, Thermo
Fisher Scientific) and 1 µg of RNA was used to synthesize
cDNA utilizing M-MLV reverse transcriptase, according to
manufacturer’s instructions (Life Technologies). Quantitative
gene expression analysis was performed using Brilliant II SYBR
Green QPCR Master Mix (Agilent Technologies, Santa Clara,
CA, USA), according to manufacturer’s recommendations.
Primers were used at a concentration of 0.5µM.We used 40 PCR
cycles as follows: denaturation 10 s at 95◦C, annealing 20 s at
60◦C and extension 20 s at 72◦C. Expression of target genes was
normalized to Gapdh. The sequences of the primers used are
indicated in Table 1.
CD4+ T-Cell Proliferation and
Differentiation in Vitro
To analyze T-cell proliferation in vivo, splenic CD4+ T-cells
were isolated from OT-II mice, stained with 10 µM CFSE
and then i.v. transferred (12.5 × 106 cells/mouse) into WT
recipient mice. One-day later mice were i.p. immunized with
TABLE 1 | Primers sequences used for quantitative RT-PCR analyses.
Gene Forward (5’ → 3’) Reverse (5’ → 3’) Reference
rorc CAGAGGAAGTCAATGTGGGA GTGGTTGTTGGCATTGTAGG Fernández et al. (2016)
runx1 TGGCACTCTGGTCACCGTCAT GAAGCTCTTGCCTCTACCGC Logan et al. (2013)
runX3 CGACCGTTTGGAGACCTGC GCGTAGGGAAGGAGCGGTCA Wang et al. (2014)
tbx21 CCTGTTGTGGTCCAAGTTCAAC CACAAACATCCTGTAATGGCTTGT Smeltz et al. (1999)
il9 CTGATGATTGTACCACACCGTGC GCCTTTGCATCTCTGTCTTCTGG Li et al. (2014)
il10 GAAGACAATAACTGCACCCA CAACCCAAGTAACCCTTAAAGTC Fernández et al. (2016)
il17a TTCATCTGTGTCTCTGATGCT AACGGTTGAGGTAGTCTGAG Fernández et al. (2016)
Il22 GACAGGTTCCAGCCCTA CAT ATCGCCTTGATCTCTCCACT Peng et al. (2014)
csf2 ACCACCTATGCGGATTTCAT TCATTACGCAGGCACAAAAG Kim et al. (2008)
grzb ATCAAGGATCAGCAGCCTGA TGATGTCATTGGAGAATGTCT Fernández et al. (2016)
ifng GAGCCAGATTATCTCTTTCTACC GTTGTTGACCTCAAACTTGG Fernández et al. (2016)
tgfb1 GCAACAACGCCATCTATGAG TATTCCGTCTCCTTGGTTCAG Fernández et al. (2016)
tgfb3 AGCGCACAGAGCAGAGAAT GTCAGTGACATCGAAAGACAG Yin et al. (2013)
drd5 CCCTAACATAACTCATCTTCTCC TAACCCTGCAAGTTCATCCA Franz et al. (2015)
gapdh TCCGTGTTCCTACCCCCAATG GAGTGGGAGTTGCTGTTGAAG Prado et al. (2012)
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25 µg OVA or just injected with vehicle (PBS). Three-days after
immunizationmice were sacrificed and spleen cells were isolated,
immunostained with fluorochrome-conjugated antibodies for
B220, CD4, TCR-Vα2 and TCR-Vβ5 and then CFSE-associated
fluorescence was analyzed in the B220− CD4+ TCR-Vα2+ TCR-
Vβ5+ gate. The extent of T-cell proliferation was determined as
the percentage of cells displaying dilution of CFSE-associated
fluorescence or by the decrease of MFI in CFSE associated
fluorescence in the CD4+ T-cell population expressing the
transgenic OT-II TCR (TCR composed by Vα2 and Vβ5 chains)
by flow cytometry. To determine the acquisition of inflammatory
phenotypes by CD4+ T-cells in vivo, naive CD4+ CD25−
CD44− CD62L+ T-cells were isolated from OT-II/cd45.2+/+
mice by cell-sorting and then i.v. transferred (105 cells/mice)
into WT/cd45.1+/+ recipient mice. One-day later, mice were
s.c. immunized with 100 µg of pOT-II in CFA and the
inflammatory phenotype of CD4+ T-cells in the draining lymph
nodes (inguinal lymph nodes) was analyzed 7 and 14 days after
immunization by intracellular cytokine staining of IL-17 and
IFN-γ .
Tregs Suppression Assay
Splenic naive CD4+ CD25− T-cells were isolated from
OT-II mice by cell-sorting, stained with 5 µM CFSE and
then co-cultured with splenic DCs on a 5:1 (T-cells:DCs)
ratio on U-bottom 96-well plates in the presence of
OVA (5 µM) for 5 days. Splenic CD4+ CD25high T-cells
(nTregs) were isolated from OT-II mice by cell-sorting and
added to the co-cultures at indicated ratios. The extent of
proliferation of naive T-cells (effector T cells; Teffs) was
determined as the percentage of cells displaying dilution
of the CFSE-associated fluorescence. One-hundred percent
proliferation corresponded to the extent of proliferation
of Teffs in the absence of nTregs (positive control). %
Suppression was calculated as 100% proliferation (from
positive control) minus % proliferation observed for each
sample.
Flow Cytometry
For analysis of cytokine production, cells were restimulated
with 1 µg/mL ionomycin and 50 ng/mL PMA in the
presence of 5 µg/mL brefeldin A for 4 h. Cell surface
staining was carried out in PBS with 2% FBS. For
intracellular staining, cells were first stained with Zombie
Aqua Fixable Viability kit (Biolegend), followed by
staining for cell-surface markers and then resuspended in
fixation/permeabilization solution (3% BSA and 0.5% saponin in
PBS). Samples including the analysis of Foxp3 transcription
factor were resuspended in fixation/permeabilization
solution (Foxp3 Fixation/Permeabilization; eBioscience)
according to the manufacturer instructions. To determine
absolute number of cells, samples were analyzed in the
presence of 123count eBeads (eBioscience) according to
manufacturer’s guidelines. Data were collected with a
Canto II (BD) and results were analyzed with FACSDiva
(BD) and FlowJo software (Tree Star, Ashlan, OR,
USA).
Statistical Analysis
Differences in means between two groups (different genotype
or different conditions) were analyzed by unpaired 2-tailed
Student’s t-test. Progression of EAE severity curves were
compared with a non-parametric Mann–Whitney rank sums
two-tailed U test. P value ≤ 0.05 was considered significant.
Analyses were performed with GraphPad Prism 6 software.
Ethics Statement
This study was carried out in accordance with the
recommendations of the institutional guidelines of Fundación
Ciencia & Vida. The protocol was approved by the Bioethics and
Biosecurity committee of the Fundación Ciencia & Vida.
RESULTS
DRD5-Signaling in Naive CD4+ T-Cells
Favors the Development of the
Inflammatory Response Associated to EAE
Since we previously appreciated a difference in the severity of
EAE manifestation between animals deficient in DRD5 confined
to DCs and animals displaying a global deficiency of DRD5
(Prado et al., 2012), we wondered whether DRD5-signaling
in other immune cells was relevant in the regulation of
the inflammatory response involved in EAE. To address this
question, we first compared how was the development of
EAE in animals displaying a global deficiency of DRD5 with
animals bearing DRD5-deficiency confined to the hematopoietic
compartment. For this purpose, we generated chimeric animals
by killing bone marrow of WT recipient animals with a
myeloablative dose of γ-irradiation and then transferring WT or
DRD5-deficient bone marrow. Eight weeks after bone marrow
transplantation, we obtained chimeric animals bearing WT or
DRD5-deficient blood cells and WT genetic background outside
the hematopoietic compartment (Supplementary Figure S1).
When EAE was induced in these chimeric animals we observed
that DRD5-deficiency confined to bone marrow resulted
in attenuated EAE manifestation (Figure 1A), although the
reduction in EAE severity was less marked than attenuation
observed between WT and DRD5KO mice (Figure 1B). Of note,
this lower difference in EAE manifestation observed between
chimeric animals bearing WT or DRD5-deficient bone marrow
may be due to the fact that the percentage of chimerism was
around 80%–85% but not complete (Supplementary Figure S1).
For this reason and also considering that autoimmune response
in EAE is driven by CD4+ T-cells, which have been described to
express DRD5 (Franz et al., 2015), we next carried out gaining of
function experiments by performing adoptive transfer of CD4+
T-cells. In this regard, we hypothesized that if DRD5-signaling
in CD4+ T-cells is relevant in contributing to the inflammation
associated to EAE, we should rescue the phenotype of DRD5KO
mice in EAE upon transfer of WT CD4+ T-cells. Accordingly,
our results show that when DRD5KO mice received the
transference of WT CD4+ T-cells, EAE severity was significantly
stronger than DRD5KO mice, although still in a lesser extent
than EAE severity observed in WT mice (Figure 1C). Since
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FIGURE 1 | DRD5-signaling in naive CD4+ T-cells favors the development of the inflammatory response associated to experimental autoimmune encephalomyelitis
(EAE). (A) Wild-type (WT) cd45.1+/+ mice were lethally irradiated and then bone marrow (107 cells/per mouse) from WT cd45.2+/+ (black symbols) or DRD5KO
cd45.2 +/+ (red symbols) mice were i.v. transferred to reconstitute the hematopoietic compartment. Eight-week later, EAE was induced by immunization with pMOG
in freund’s complete adjuvant (CFA) followed by Pertussis Toxin injection and disease severity was daily determined throughout the time-course of disease
development. Values represent mean ± SEM with n = 5–6 mice per group. ∗∗p < 0.01 by Mann-Whitney U-test. (B) EAE was induced in WT (black symbols) and
DRD5KO (red symbols) mice by immunization with pMOG in CFA followed by Pertussis Toxin injection and disease severity was daily determined throughout the
time-course of disease development. Values represent mean ± SEM with n = 4–7 mice per group. ∗∗p < 0.01 by Mann-Whitney U-test. (C) Total splenic CD4+
T-cells were isolated from WT mice by negative selection using magnetic beads-based kit (from Miltenyi) and then they were i.v. injected into DRD5KO mice (5 × 106
cells/per mouse; white symbols). One-day later, EAE was induced by immunization with pMOG in CFA followed by Pertussis Toxin injection and disease severity was
daily determined throughout the time-course of disease development. EAE was also induced in WT (black symbols) and untransferred DRD5KO (red symbols) mice
as control groups. Values represent mean ± SEM with n = 4 mice per group. ∗p < 0.05 and ∗∗∗∗p < 0.0001 WT vs. untransferred DRD5KO mice; ##p < 0.01 and
####p < 0.0001 WT vs. transferred DRD5KO; &&&p < 0.001 transferred vs. untransferred DRD5KO mice by Mann-Whitney U-test. (D) Naive CD4+ T-cells (CD4+
CD25− CD62L+ CD44−) were isolated from WT mice by cell-sorting and then they were i.v. injected into DRD5KO mice (3 × 106 cells/per mouse; white symbols).
One-day later, EAE was induced by immunization with pMOG in CFA followed by Pertussis Toxin injection and disease severity was daily determined throughout the
time-course of disease development. EAE was also induced in WT (black symbols) and untransferred DRD5KO (red symbols) mice as control groups. Values
represent mean ± SEM with n = 3–4 mice per group. ∗p < 0.05 WT vs. untransferred DRD5KO mice; &&p < 0.01 transferred vs. untransferred DRD5KO mice by
Mann-Whitney U-test.
Tregs, a subpopulation of CD4+ T-cells, play a relevant role
attenuating EAE development in late stages of the disease
manifestation (Petermann et al., 2010) and they also express
DRD5 (Kipnis et al., 2004; Cosentino et al., 2007), we next wanted
to evaluate the effect of DRD5-signaling confined to CD4+
T-cells without the potential contribution of DRD5-signaling
from Tregs. For this purpose, we next performed a set of
experiments in which we isolate naive CD25− CD4+ CD44−
CD62L+ T-cells from WT mice, a subset devoid of Tregs
cells (CD25high CD4+), and then these cells were transferred
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into DRD5KO recipient mice just before EAE induction. The
results show that the transfer of DRD5-sufficient naive CD4+
T-cells, in the absence of Tregs, into DRD5-defficient animals
results in a complete rescue in EAE manifestation, displaying
similar EAE severity than observed for WT mice (Figure 1D).
Thereby, these results indicate that DRD5-signaling in naive
CD4+ T-cells exerts a pro-inflammatory role favoring EAE
development.
DRD5-Signaling in CD4+ T-Cells
Potentiates T-Cell Activation
To address the question of how DRD5-signaling favors the
inflammatory potential of CD4+ T-cells we next evaluated
the role of this receptor in T-cells activation. Accordingly,
we first determined the role of DRD5-signaling in the
proliferation of CD4+ T-cells in vivo, which is directly related
with the potency of T-cell activation. For this purpose, we
performed adoptive transfer experiments using CD4+ T-cells
from OT-II transgenic mice, which express a transgenic
T-cell receptor (TCR) specific for the recognition of a
peptide derived from the chicken ovalbumin (OVA323–339;
pOT-II). To determine T-cell activation in vivo, we isolate
CD4+ T-cells from WT/OT-II or from DRD5KO/OT-II
mice, which were loaded with the fluorescent probe CFSE
and then transferred into WT recipient mice. Subsequently,
transferred mice were immunized with pOT-II in CFA and
the potency of proliferation induced in pOT-II-specific T-cells
was determined 3 days later in the spleen as the extent of the
dilution of CFSE-associated fluorescence as previously described
FIGURE 2 | DRD5-signaling in CD4+ T-cells potentiates T-cell activation. (A,B) CD4+ T-cells were isolated from WT/OT-II or DRD5KO/OT-II mice by negative
selection using magnetic beads-based kit (from Miltenyi), stained with 10 µM carboxyfluorescein succinimidyl ester (CFSE) and then i.v. transferred (12.5 × 106
cells/mice) into WT recipient mice. One-day later mice were i.p. immunized with 25 µg ovalbumin (OVA) or just injected with vehicle (PBS). Three-day after
immunization mice were sacrificed and spleen cells were isolated, immunostained with fluorochrome-conjugated antibodies for B220, CD4, TCR-Va2 and
TCR-Vβ5 and then CFSE-associated fluorescence was analyzed in the B220− CD4+ TCR-Va2+ TCR-Vβ5+ gate. (A) Representative histograms of CFSE-associated
fluorescence vs. number of cells (events) are shown. Markers delimiting proliferating cells are shown. Percentages of CD4+ T-cells in the region of proliferating cells
are indicated. (B) Percentages of CD4+ T-cells in the proliferating area from three independent experiments are represented in the bars graphs. Values represent
mean ± SEM. ∗p < 0.05 by unpaired Student’s t-test. (C,D) Naive CD4+ CD25− CD62L+ CD44− T-cells were isolated from WT/OT-II or DRD5KO/OT-II mice by
cell-sorting, stained with 10 µM CFSE and then co-cultured with splenic Dendritic cells (DCs) isolated by positive CD11c+ selection using magnetic beads based kit
(from Miltenyi) at a ratio of CD4+ T-cells:DCs = 5:1, in the presence of pOT-II (200 ng/ml) for 48 h or 72 h. (C) Cells were immunostained with
fluorochrome-conjugated antibodies for CD4, TCR-Va2 and TCR-Vβ5 and then CFSE-associated fluorescence was analyzed in the CD4+ TCRVa2+ TCRVβ5+ gate.
Representative histograms of CFSE-associated fluorescence vs. number of cells (events) are shown. Markers delimiting proliferating cells are shown. Percentages of
CD4+ T-cells in the region of proliferating cells are indicated. (D) IL-2 production was determined in the culture supernatant by ELISA. Data from three independent
experiments is shown. Values represent mean ± SEM. ∗p < 0.05 by unpaired Student’s t-test.
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(Contreras et al., 2016). The results show that DRD5-deficiency
resulted in attenuated CD4+ T-cell proliferation as indicated
by a lower percentage of OT-II cells displaying dilution
of CFSE-associated fluorescence (Figures 2A,B). To obtain
further evidence in the role of DRD5-signaling in CD4+
T-cell activation, we next performed in vitro experiments
in which antigen-specific T-cell activation was induced by
incubating naive CD4+ T-cells isolated from WT/OT-II or
DRD5KO/OT-II in the presence or WT DCs loaded with OVA.
To evaluate the potency of T-cell activation, we determined
the extent of proliferation as the level of CFSE dilution and
the secretion of IL-2 into the culture supernatant, which
corresponds to the main T-cell growth factor. The results
show that DRD5-deficiency in CD4+ T-cells not only resulted
in decreased proliferation (Figure 2C) but also in reduced
IL-2 production (Figure 2D). Thus, these results indicate that
DRD5-signaling potentiates CD4+ T-cell activation in vitro and
in vivo.
DRD5-Signaling in CD4+ T-Cells Favors the
Acquisition of Th17 Phenotype
To gain deeper insight in the role of DRD5-signaling in
the CD4+ T-cell response, we next determined how this
receptor affects the differentiation of naive CD4+ T-cells into
effector phenotypes. Because the Th1 and Th17 are the main
subsets of effector T-cells (Teffs) driving the inflammatory
response involved in EAE (Prado et al., 2013) and both
of them express DRD5 transcripts (Supplementary Figure
S2), we next evaluated the potential role of DRD5-signaling
in the acquisition of these functional phenotypes. For this
purpose, we performed experiments in which naive CD4+
T-cells were isolated from WT/OT-II or from DRD5KO/OT-
II mice and transferred into WT recipients. Afterward, these
recipient mice were subcutaneously immunized with pOT-II
and then the extent of acquisition of Th1 and Th17 functional
phenotypes by the transferred CD4+ T-cells was analyzed in
the draining lymph nodes at different time points. The results
show that despite there were no significant differences in
the absolute number and frequency of Th1 cells (see IFN-
γ+ IL-17− T-cells in Figure 3A and in Figure 3B middle
panels), DRD5-deficiency in CD4+ T-cells resulted in a strong
reduction in the absolute number of Th17 cells in the draining
lymph nodes 1 week after immunization (see IFN-γ− IL-17+
T-cells in Figures 3A and in Figure 3B right-bottom panel).
DRD5-deficiency in CD4+ T-cells resulted also in a trend
of decreased Th17 frequency in the draining lymph nodes
1 week after immunization, although this difference was not
statistically significant (Figure 3B right-top panel). To evaluate
whether difference in the acquisition of functional phenotypes
observed between DRD5-deficient and DRD5-suficient CD4+
T-cells was due to altered viability of these cells, we determined
the percentage of living cells among transferred CD4+ T-cells.
The analyses show that frequencies of viable cells were similar
in both genotypes, ruling out this possibility (Supplementary
Figure S3A). Interestingly, irrespective of the genotype of CD4+
T-cells, the absolute number of Th1 OT-II CD4+ T-cells in the
draining lymph nodes was increased after 2 weeks (Figure 3B
middle-bottom panel), whilst the number of Th17 OT-II CD4+
T-cells was strongly reduced (Figure 3B right-bottom panel),
which is probably explained by the faster exit of Th17 cells
FIGURE 3 | DRD5-signaling in CD4+ T-cells favors the acquisition of Th17 phenotype. (A,B) Naive CD4+ CD25− T-cells were isolated from WT/OT-II/cd45.2+/+ or
DRD5KO/OT-II/cd45.2+/+ mice by cell-sorting and then i.v. transferred (105 cells/mouse) into WT/cd45.1+/+ recipient mice. One-day later, mice were s.c.
immunized with 100 µg of pOT-II in CFA and CD4+ T-cells were analyzed by flow cytometry in the draining lymph nodes (inguinal lymph nodes) 7 and 14 days after
immunization. (A) Representative contour-plots analyzing IFN-γ vs. IL-17 in the CD45.2+ CD4+ gated population. Numbers in each quadrant represent the
percentage of cells in the corresponding quadrant. (B) Quantification of the percentage (top panels) and absolute number (bottom panels) of total CD4+ T-cells (left
panels), Th1 cells (central panels) and Th17 cells (right panels) contained in the CD45.2+ population. Values represent mean ± SEM with n = 4 mice per group.
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 by unpaired Student’s t-test.
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from the draining lymph nodes after activation (Dardalhon
et al., 2008; Reboldi et al., 2009). It is also noteworthy that,
irrespective of their phenotype and genotype, the frequency
of total OT-II CD4+ T-cells transferred is reduced in the
draining lymph nodes 2 weeks after immunization (Figure 3B
left-top panel) even when the absolute number is increased
(Figure 3B left-bottom panel). This fact is likely to be due
to the activation of endogenous CD4+ T-cells (CD45.1+)
with specificity for pOT-II or for different antigens from
mycobacterium tuberculosis contained in the CFA used as
adjuvant in these experiments. To further explore the role
of DRD5-signaling in Teffs, we quantified the transcriptional
levels of a panel of different cytokines and transcription factors
involved in the effector function of Th1 and Th17 cells. For
this purpose, we performed a quantitative RT-PCR array of
a set of relevant functional molecules in naive CD4+ T-cells,
Th1 and Th17 cells obtained from WT or DRD5KO mice.
To gain a deeper insight in the role of DRD5-signaling in
Th17 function, we evaluated the transcriptional panel of these
molecules in Th17 cells differentiated in pathogenic (Th17p)
or non-pathogenic (Th17np) conditions (Lee et al., 2012). The
results show that DRD5-deficiency results in decreased IFN-γ
transcription by naive CD4+ T-cells or Th17np (Figure 4A left
and right panels, and Figure 4B), increased transcription of
IL-10 and IL-22 by Th17p (Figure 4A middle-right panel, and
Figure 4B), exacerbated transcription of IL-17 and IL-22 by Th1
(Figure 4A middle-left panel, and Figure 4B) and increased
transcription of granzyme B and IL-22 by naive CD4+ T-cells
(Figure 4A left panel, and Figure 4B). Of note, we observed
similar frequency of viable cells after CD4+ T-cell differentiation
(Supplementary Figure S3B), ruling out the possibility that
differential expression of cytokines and transcription factors was
due to altered cell viability. Taken together, these results suggest
that DRD5-defficiency in CD4+ T-cells results in impaired
acquisition of the inflammatory Teff phenotypes and reduced
expansion of Th17 cells.
DRD5-Signaling in Tregs Favors Their
Suppressive Activity
Since we observed that the transference of DRD5-sufficient
total CD4+ T-cells into DRD5KO mice just partially rescues
the phenotype on EAE manifestation (Figure 1C), whilst the
transference of DRD5-sufficient naive CD25− CD4+ CD44−
FIGURE 4 | DRD5-deficiency alters the transcriptional pattern of different effector phenotypes of CD4+ T-cells. Splenic naive (CD4+ CD62L+ CD44−CD25−) T-cell
were isolated from WT or DRD5KO mice by cell-sorting and immediately analyzed (Tn) or stimulated with anti-CD3 and anti-CD28 Abs in the presence of biased
conditions to differentiate to Th1, Th17p or Th17np for 5 days and then analyzed. Afterward, total RNA was extracted and the transcription of a panel of relevant
genes was analyzed by qRT-PCR. Gapdh transcription was used as house keeping. (A) Data represented as infold (WT relative to DRD5KO) indicating how many
times the levels of mRNA obtained in WT duplicates those obtained in DRD5KO. (B) Data represented as Ln of mRNA levels/house keeping (WT vs. DRD5KO).
Central diagonal dotted line indicates same mRNA levels. External dotted lines indicate 2-fold mRNA levels and external solid lines indicate 4-fold mRNA levels.
(A,B) Values are the mean from three independent experiments.
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CD62L+ T-cells into DRD5KO mice completely rescues the
phenotype on EAEmanifestation (Figure 1D), we next wondered
whether DRD5-signaling plays a relevant role in the Tregs
(CD25high CD4+) response. To address this question, we first
determined the effect of DRD5-signaling in the suppressive
activity of Tregs. For this purpose, we performed in vitro
assays in which WT naive OT-II CD4+ T-cells (Teff) were
loaded with CFSE, activated with OVA-loaded DCs and
co-incubated with increasing concentrations of DRD5-defficient
or DRD5-sufficient OT-II Tregs and the extent of inhibition
of Teff proliferation was quantified. The results show that
DRD5-sufficient Tregs exert a stronger inhibition of Teff
proliferation than that exerted by DRD5-defficient Tregs
(Figures 5A,B), thus indicating that DRD5-signaling favors a
stronger suppressive activity by Tregs. To evaluate whether
DRD5-signaling in Tregs plays a relevant role in the suppressive
activity in vivo, we next performed experiments in which
DRD5-sufficient or DRD5-defficient Tregs were transferred into
WT recipient mice just before EAE induction. In the same
direction of conclusions obtained from in vitro experiments
(Figures 5A,B), these results show that EAE severity was
reduced by DRD5-sufficient Tregs in a higher extent than
that exerted by DRD5-defficient Tregs (Figure 5C), thus
indicating that DRD5-signaling in Tregs favors a more potent
suppressive activity in vivo. It is noteworthy that there was not
differences in the extent of attenuation of EAE manifestation
exerted by DRD5-sufficient and DRD5-defficient Tregs until
late stages (after day 15 post-induction) in the time-course
of EAE development, indicating that DRD5-signaling in Tregs
was relevant only in late stages of EAE manifestation. To
gain insight in the mechanism of how DRD5-signaling favors
the suppressive activity of Tregs, we next evaluated the
transcriptional level of the main cytokines associated to Tregs
function, IL-10 and TGF-β, however we did not find any
difference between DRD5-sufficient and DRD5-defficient Tregs
(Figure 5D). To confirm whether IL-10 production was not
affected by DRD5-signaling in Tregs we also analyzed the extent
of IL-10 production at the level of protein and we found no
differences between WT and knockout cells (Supplementary
Figure S4). To further explore how DRD5-signaling potentiates
the suppressive activity of Tregs, we next evaluated the level
of protein expression of a panel of surface molecules and
FIGURE 5 | DRD5-signaling in Tregs favors their suppressive activity in vitro and in vivo. (A,B) Splenic CD4+ CD25− T-cells (Teff) were isolated from WT/OT-II mice by
cell-sorting, stained with 5 µM CFSE and then co-cultured with splenic DCs isolated from WT mice by positive CD11c+ selection using magnetic beads based kit
(MACS) at a ratio of CD4+ T-cells:DCs = 5:1, in the presence of OVA (5 µM) for 5 days. Splenic CD4+ CD25high T-cells (nTregs) were isolated from WT/OT-II or
DRD5KO/OT-II mice by cell-sorting and added to the co-cultures at indicated ratios. (A) Representative histograms of CFSE-associated fluorescence vs. number of
cells (events) in the CD4+ TCR-Va2+ TCR-Vβ5+ gate are shown. Markers delimiting proliferating cells are indicated. Percentage of CD4+ T-cells in the region of
proliferating cells are indicated. (B) Percentages of suppression of Teff proliferation from three independent experiments are represented in the bars graphs.
One-hundred percent proliferation corresponds to the extent of proliferation of Teffs in the absence of nTregs (positive control). % Suppression is calculated as 100%
proliferation (from positive control) minus % proliferation observed for each sample. Values represent mean ± SEM. ∗p < 0.05 by unpaired Student’s t-test.
(C) Splenic CD4+ CD25high T-cells (nTregs) were isolated from WT (gray symbols) or DRD5KO (red symbols) mice by cell-sorting and i.v. transferred into WT recipient
mice (7 × 105 cells per mouse). One-day later, EAE was induced by immunization with pMOG in CFA followed by Pertussis Toxin injection and disease severity was
daily determined throughout the time-course of disease development. EAE was also induced in untransferred WT (black symbols) as a control group. Values
represent mean ± SEM with n = 3–12 mice per group. ##p < 0.01 untransferred WT vs. DRD5KO nTregs transferred into WT mice; ∗∗p < 0.01 and ∗∗∗p < 0.001
untransferred WT vs. WT nTregs transferred into WT mice; &p < 0.05 WT nTregs transferred into WT mice vs. DRD5KO nTregs transferred into WT mice by
Mann-Whitney U-test. (D) Splenic CD4+ CD25high T-cells (nTregs) were isolated from WT or DRD5KO mice by cell-sorting and immediately analyzed (resting) or
activated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 for 36 h (activated). Afterward, total RNA was extracted and the levels of transcripts for
TGF-β and IL-10 were quantified by real time RT-PCR. Data is represented as the levels of transcripts relative to the house-keeping gapdh. Values represent
mean ± SD from at least three independent experiments. No significant differences were found between different genotypes.
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FIGURE 6 | DRD5-signaling favors glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) expression in Tregs. Splenic CD4+ CD25high T-cells
(nTregs) were isolated from WT or DRD5KO mice by cell-sorting and immediately analyzed (resting) or activated with anti-CD3 and anti-CD28 antibodies in the
presence of IL-2 for 36 h (activated). Cells were immunostained for a panel of surface markers associated to Tregs function, then permeabilized and immunostained
for Foxp3 and analyzed by flow cytometry. (A) Representative dot plots are shown. Percentage of cells in each quadrant associated to immunostaining of each
molecule is indicated. Data from activated (B) and resting (C) Tregs are represented as MFI. Values represent mean ± SD from at least four independent
experiments. ∗∗p < 0.01 by unpaired Student’s t-test.
transcription factor associated with the suppressive activity
of Tregs. The results show that the only difference detected
between DRD5-sufficient and DRD5-defficient Tregs was that
DRD5-deficiency results in a significant reduction in the
expression of GITR (Figures 6A,B), a molecule that has been
related with the expansion of Tregs (Ronchetti et al., 2015).
Of note, this difference in GITR expression was observed
only in activated Tregs (Figure 6B), but not in resting
conditions (Figure 6C). Thus, these results together indicate
that DRD5-signaling in Tregs plays a relevant role favoring
Tregs-mediated suppressive response, an effect that would
be exerted at least in part by increasing the expression of
GITR.
DISCUSSION
Our findings here described represent the first genetic evidence
indicating a relevant role of DRD5-signaling in the CD4+
T-cell response involved in EAE. Interestingly these findings
suggest a dual role of DRD5-signaling, which are manifested at
different stages during the time-course of EAE development and
trigger opposite outcomes. Whereas the stimulation of DRD5 in
naive CD4+ T-cells potentiates the inflammatory Th17-driven
response early after the onset of the disease, DRD5-signaling in
Tregs favors the suppressive activity of these cells dampening
inflammation just once the peak of disease manifestation has
been reached. Thus, these findings contribute to a better
understanding of the complex regulation of the CD4+ T-cell
driven autoimmune response involved in EAE and also illustrate
how depending on the timing and on the precise T-cell subset,
neuroimmune communications may exert different outcomes.
In a previous study, we showed genetic and pharmacologic
evidence indicating that DRD5-signaling in CD4+ T-cells
favored T-cell activation in vitro, a process that was mediated
by ERK1/2 phosphorylation (Franz et al., 2015). In the
same study we appreciated that DRD5-signaling in CD4+
T-cells had no effect in the process of Th1 differentiation
in vitro. According with this previous study, our present results
indicate that DRD5-signaling is relevant in vivo favoring T-cell
activation (Figure 2) and without effect in the acquisition
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of the Th1 phenotype (Figure 3). Moreover, in agreement
with our results about the role of DRD5-signaling in the
effector CD4+ T-cell response in vivo, previous studies have
shown pharmacologic evidence suggesting that the systemic
antagonism of type I DRs attenuates the potency of Th17-driven
responses (Nakano et al., 2008, 2011; Hashimoto et al.,
2009; Okada et al., 2009; Nakagome et al., 2011; Nakashioya
et al., 2011). In this regard, the systemic administration of
the type I DRs antagonist SCH23390 reduces the clinical
manifestation of EAE in mice immunized with a peptide
derived from myelin proteolipid protein (Nakano et al.,
2008). Similarly, subsequent studies showed that the same
drug attenuates the inflammatory response in collagen-induced
arthritis (Nakano et al., 2011; Nakashioya et al., 2011), allergic
asthma (Nakagome et al., 2011; Gong et al., 2013), diabetes
(Hashimoto et al., 2009) and nephrotoxic serum nephritis
(Okada et al., 2009). Mechanistic analyses suggested that the
therapeutic effect exerted by SCH23390 in these inflammatory
disorders is due to the type I DRs antagonism in both
CD4+ T-cells and DCs. Addressing the molecular mechanism
involved in type I DRs signaling in CD4+ T-cells, the evidence
suggests that type I DRs stimulation promotes B-cell activating
transcription factor activity, favoring RORγt up-regulation and
consequently Th17-mediated responses, which is inhibited by
SCH23390 (Gong et al., 2013). Nevertheless, the pharmacologic
approach used in all those studies does not allow the
discrimination between the effects mediated by DRD5 or
DRD1 since the drug inhibits both type I DRs with similar
affinities (Bourne, 2001). Here we present genetic evidence
indicating an important role of DRD5-signaling in promoting
the acquisition of Th17 inflammatory phenotype in vivo
(Figure 3).
Two previous studies have addressed the role of dopaminergic
regulation of Tregs function (Kipnis et al., 2004; Cosentino
et al., 2007). In apparent controversy with the present work,
the studies carried out by Kipnis et al. (2004) and Cosentino
et al. (2007) indicated that type I DRs stimulation attenuates
Tregs suppressive activity by using a pharmacologic approach.
Nonetheless, these studies were performed with drugs that
cannot discriminate between their effects mediated by DRD1 or
DRD5, as those drugs display very similar affinities for both
receptors (Kipnis et al., 2004; Cosentino et al., 2007). Thus, it
is likely that the inhibitory effect of dopamine or dopaminergic
analogs on Tregs activity appreciated in those studies was
mediated by DRD1 rather than DRD5. Here, we show genetic
evidence indicating unequivocally that DRD5-deficiency in Tregs
results in impaired suppressive activity of these cells in vitro and
in vivo (Figure 5).
With these results in mind arise the question of where
and when dopamine is relevant as a source available for
CD4+ T-cells. In this regard, relevant sources of dopamine
have been described in secondary lymphoid organs, the organs
where T-cell responses are initiated, as well as in some target
organs, where effector CD4+ T-cells promote inflammation.
For instance, secondary lymphoid organs such as lymph nodes
and the spleen are highly innervated by sympathetic fibers
immunoreactive for dopamine (Weihe et al., 1991; Haskó
and Szabó, 1998). In this way, the peripheral nervous system
might exert regulation of the initiation of T-cell responses
(Ben-Shaanan et al., 2016). According to this possibility, the
present results (Figures 2, 3) and previous studies (Pacheco
et al., 2014) suggest that dopamine produced in draining
lymph nodes shapes the expansion and differentiation of
naive CD4+ T-cells toward the different functional T-cell
phenotypes. In addition to the sympathetic fibers, DCs and
follicular helper T-cells (TFH) may also represent important
sources of dopamine in secondary lymphoid organs. Indeed,
we have recently described how dopamine contained in DCs
plays an important role potentiating Th1 and Th17 responses
involved in EAE (Prado et al., 2012, 2018). Furthermore,
Papa et al. (2017) recently described how TFH produce high
amounts of dopamine and release it upon cognate interaction
with B-cells in the germinal center, thus accelerating the
production of high-affinity antibodies by plasma-cells. Thereby,
dopamine produced in different specific locations inside
secondary lymphoid organs might strengthen the initiation
and development of adaptive immunity. With regard to the
organs target of inflammation as potential relevant sources
of dopamine for regulation of effector CD4+ T-cell response,
altered levels of dopamine in different structures of the brain
have been associated with neuroinflammation involved in some
neurodegenerative disorders. For instance, dopamine levels have
been found to be dramatically reduced in the nigrostriatal
pathway of Parkinson’s disease patients as well as in animal
models of this disorder (Ehringer and Hornykiewicz, 1960;
Brochard et al., 2009). We have previously suggested that
this pathologic reduction in dopamine levels results in the
selective stimulation of the DR displaying the highest affinity
for dopamine, the DRD3 (Pacheco, 2017). In this regard, we
have previously found that DRD3-signaling triggers a strong
inflammatory behavior of CD4+ T-cells that infiltrate the
brain in an animal model of Parkinson’s diseases favoring
the neurodegenerative process in the nigrostriatal pathway
(González et al., 2013). On the other hand, EAE, the animal
model used here to study MS and the autoimmune response
associated, involves an increase of dopamine levels in the
striatum during the peak of the disease (Balkowiec-Iskra et al.,
2007). Since we observed a role of DRD5 in Tregs only
once the peak of EAE manifestation has been reached, our
results here suggest that the increase of striatal dopamine
would be relevant stimulating DRD5 in Tregs, thus favoring
their suppressive activity and dampening disease manifestation
(Figure 5). Another potential source of dopamine present in
the tissues target of inflammation may be Tregs. According
to this idea, Tregs represent an important CD4+ T-cell subset
infiltrating the brain and spinal cord during late stages of
EAE manifestation, which is associated with the recovery phase
of the disease (Petermann et al., 2010). Moreover, these cells
have been described to synthesize and store important amounts
of dopamine, which can be released upon treatment with
reserpine (Cosentino et al., 2007). Despite the endogenous
stimulus triggering dopamine release from Tregs has not been
found yet, IFN-β has been proposed as a plausible candidate
(Cosentino et al., 2012). Taken together these studies suggest
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that dopamine produced in the secondary lymphoid organs
may strengthen the initial development of adaptive immune
responses, whilst dopamine present in the inflamed target
tissue may shape the effector and suppressive T-cell response
depending in the timing and in the precise levels of available
dopamine.
Interestingly, not only the CNS may represent a target tissue
of inflammation with relevant sources of dopamine, but also
the gut mucosa. In this regard, the gut mucosa has been found
to be a major source of dopamine in healthy conditions, a
source that is strongly reduced upon inflammation (Magro et al.,
2002, 2004; Asano et al., 2012). Previous evidence has suggested
that in healthy conditions high dopamine levels in the gut
promote the stimulation of the low affinity DRs, specially the
DRD2, whilst under inflammatory conditions low dopamine
levels favors the selective stimulation of DRD3 (Pacheco,
2017). Furthermore, whereas DRD3-stimulation has been
shown to promote pro-inflammatory CD4+ T-cell responses
in the gut mucosa, including Th1 and Th17-driven immunity
(Contreras et al., 2016), DRD2-signaling has been associated
with anti-inflammatory effects (Pacheco et al., 2014). Indeed, a
genetic polymorphism of DRD2 gene, which results in decreased
receptor expression, has been reported as a risk factor for
inflammatory bowel diseases (Magro et al., 2006). Accordingly,
although the frequency of Tregs was not changed in the gut,
suppressive activity of intestinal Tregs was compromised in
inflammatory colitis (Wu et al., 2014), a condition associated
to decreased dopamine levels (Magro et al., 2004). Interestingly,
the impairment of suppressive Tregs function was abolished
by the administration of cabergoline, a DRD2 agonist (Wu
et al., 2014). Thus, these results together suggest that, whereas
DRD2-signaling in Tregs promotes suppressive function in
a healthy gut mucosa containing high dopamine levels, the
selective DRD3-signaling in the inflamed gut mucosa containing
low dopamine levels favors the inflammatory potential of effector
CD4+ T-cells promoting further inflammation.
It is noteworthy that one of the main sources of dopamine
present in the gut mucosa is given by the commensal gut
microbiota. In this regard, it has been described that most
dopamine arrives to the gut mucosa as glucuronide conjugated,
which is biologically inactive. Nevertheless, Clostridium species
present in the gut microbiota express β-glucuronidase activity,
which catalyzes the production of free dopamine in the gut
mucosa (Asano et al., 2012). In addition, recent studies have
shown in vitro evidence indicating that some components of
gut microbiota, including Bacillus cereaus, Bacillus mycoides,
Bacillus subtilis, Proteus vulgaris, Serratia marcescens, S. aureus,
E. coli K-12, Morganella morganii, Klebisella pneumoniae and
Hafnia alvei, can also produce dopamine (Clark and Mach,
2016). Of note, a recent study performed with 34 monozygotic
twin pairs discordant for MS has shown that when microbiota
from the MS twin is transplanted into a transgenic mouse
model of spontaneous brain autoimmunity, mice developed
autoimmunity with higher incidence than when transplanted
with microbiota coming from the healthy twin (Berer et al.,
2017). Importantly, when mice were transplanted with
microbiota obtained from MS twins, immune cells present
in the gut mucosa produced significantly lower levels of the
anti-inflammatory cytokine IL-10 than those immune cells of
animals receiving microbiota coming from healthy twins. In
addition, the analysis in the composition of gut microbiota
shows clear differences between healthy and MS twins (Berer
et al., 2017). Taken together, these findings indicate that gut
microbiota, which can strongly regulate dopamine levels present
in the gut mucosa, constitutes a pivotal factor in the control of
gut inflammation and in the triggering of MS.
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